MN-25

• Description:

  MN-25 (compound 4a) is an orally active indolpyridone that serves as a novel cannabinoid ligand. MN-25 has Ki of 245 nM and 11 nM for CB1 and CB2. MN-25 has CB2 agonist activity and inhibits TNF-R release in human peripheral blood mononuclear cells in vitro with an IC50 of 33 μM. MN-25 shows efficacy in a mouse acute inflammation model at oral doses up to 50 mg/kg>[1].

• UNSPSC:

  12352005

• Target:

  Cannabinoid Receptor; TNF Receptor

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; GPCR/G Protein; Neuronal Signaling

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology; Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/mn-25.html

• Smiles:

  C[C@]1(C[C@](CC1)([H])C2(C)C)[C@@H]2NC(C3=CN(C4=C(OC)C=CC=C43)CCN5CCOCC5)=O

• Molecular Formula:

  C26H37N3O3

• Molecular Weight:

  439.59

• References & Citations:

  [1]Stephen T Wrobleski, et al. Rational design and synthesis of an orally active indolopyridone as a novel conformationally constrained cannabinoid ligand possessing antiinflammatory properties. J Med Chem. 2003 May 22;46 (11) :2110-6.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  CB1; CB2

• CAS Number:

  [501926-82-5]